Comment: EBCC 2024 highlights

Share :
Published: 25 Apr 2024
Views: 41
Rating:
Save
Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) discuss the highlights from EBCC 2024.

Dr Poulakaki starts the discussion by talking about the PREFERABLE-EFFECT study and the MARI trial.

Dr Ignatiadis explains the results and highlights the significance of the results from the ALEXANDRA/IMpassion030 phase III trial. He also talks about the Keynote 522 study and the I-SPY2 trial.